ALICIA VOGLESON: Open Payments
NPI 1952825168 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,034 in 23 payments from 15 companies in 2025. Trend: 2023 $1,153 · 2024 $670 · 2025 $1,034
Food & beverage: $1,034
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $154 |
| Astellas Pharma US Inc | 2 | $142 |
| Novo Nordisk Inc | 4 | $125 |
| Xeris Pharmaceuticals, Inc. | 1 | $122 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $76 |
| Alkermes, Inc. | 1 | $72 |
| GlaxoSmithKline, LLC. | 1 | $69 |
| Tactile Systems Technology Inc | 1 | $67 |
| Lilly USA, LLC | 2 | $52 |
| PFIZER INC. | 2 | $50 |
Products named: Veozah, FASENRA, RECORLEV, JARDIANCE, Ozempic, LYBALVI, NUCALA, Flexitouch Plus.
Industry payments across DE — which companies pay providers there.
